Browsing Artículos by Subject "Second-line therapy"
Now showing items 1-1 of 1
A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma Purpose Patients with recurrent glioblastoma (rGBM) have a poor prognosis, with survival ranging from 25 to 40 weeks. Antiangiogenic agents are widely used, showing a variable response. In this study, we explored the efcacy ...